Protective Effect and Possible Mechanisms of Artemisinin and Its Derivatives for Diabetic Nephropathy: A Systematic Review and Meta-Analysis in Animal Models

Background. Artemisinin and its derivatives have potential antidiabetic effects. There is no evaluation of reported studies in the literature on the treatment of diabetic nephropathy (DN), one of the commonest diabetic microangiopathies, with artemisinins. Here, we aimed to evaluate preclinical evid...

Full description

Saved in:
Bibliographic Details
Published in:Oxidative medicine and cellular longevity 2022, Vol.2022, p.5401760-20
Main Authors: Feng, Haoyue, Wu, Tingchao, Zhou, Qi, Li, Hui, Liu, Tianyi, Ma, Xitao, Yue, Rensong
Format: Article
Language:English
Subjects:
Animal research
Animals
Antidiabetics
Artemisinins - pharmacology
Artemisinins - therapeutic use
Bias
Diabetes
Diabetes Mellitus - drug therapy
Diabetic Nephropathies - drug therapy
Diabetic nephropathy
Drug dosages
Female
Humans
Kidney diseases
Laboratory animals
Male
Meta-analysis
Models, Animal
Proteinuria
Review
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Artemisinin and its derivatives have potential antidiabetic effects. There is no evaluation of reported studies in the literature on the treatment of diabetic nephropathy (DN), one of the commonest diabetic microangiopathies, with artemisinins. Here, we aimed to evaluate preclinical evidence for the efficacy and possible mechanisms of artemisinins in reducing diabetic renal injury. Methods. We conducted an electronic literature search in fourteen databases from their inception to November 2021. All animal studies assessing the efficacy and safety of artemisinins in DN were included, regardless of publication or language. Overall, 178 articles were screened according to predefined inclusion and exclusion criteria. Finally, 18 eligible articles were included in this systematic review. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) risk-of-bias tool was used to assess the risk of bias in the included studies. The primary outcomes were kidney function, proteinuria, and renal pathology. Secondary endpoints included changes in fasting plasma glucose (FPG) levels, body weight, and relevant mechanisms. Results. Of the 18 included articles involving 418 animal models of DN, 1, 2, 6, and 9 used dihydroartemisinin, artemether, artesunate, and artemisinin, respectively. Overall, artemisinins reduced indicators of renal function, including blood urea nitrogen (P
ISSN:1942-0900
1942-0994
1942-0994
DOI:10.1155/2022/5401760